Atara Biotherapeutics, Inc. (NASDAQ:ATRA) will be discussing 3Q20 financial results with the investment community.on 9th November 2020 at 4:30 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.atarabio.com
Earnings Expectation
Atara Biotherapeutics, Inc. is expected to report third quarter earnings results, after market close, on Monday 9th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 1.09 per share. Looking ahead, the full year loss are expected at $ 4.53 per share.
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and autoimmune and viral diseases, including ATA2271 for mesothelin; ATA2321 for acute myeloid leukemia; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 and ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis.
